Purpose of review In addition to the recent progresses in the description of the genetic landscape of B-cell non-Hodgkin's lymphomas, tumor microenvironment has progressively emerged as a central determinant of early lymphomagenesis, subclonal evolution, drug resistance, and late progression/transformation. The purpose of this review is to outline the most recent findings regarding malignant B-cell niche composition and organization supporting direct and indirect tumor-promoting functions of lymphoma microenvironment.
INTRODUCTION
B-cell non-Hodgkin's Lymphomas (B-NHL) are a group of heterogeneous neoplasias corresponding to clonal expansion of mature B cells arrested at various stages of differentiation and disseminated preferentially within secondary lymphoid organs and bone marrow [1] . The current WHO identifies more than 30 entities with specific phenotypic, genetic, and clinical features as well as variable degrees of dependence on external stimuli for survival and proliferation. Follicular lymphoma and diffuse large B-cell lymphomas (DLBCL), the two most common B-NHL, are both derived from germinal center B cells (GCBs) but are characterized by opposite patterns of tumor niche composition and organization, making them interesting models to understand how these two parameters could influence lymphomagenesis dynamic [2, 3] .
Follicular lymphoma is the paradigm of a B-cell malignancy dependent on a germinal center-like permissive microenvironment including CD4 pos T cells, myeloid cells, and stromal cells with specific phenotypic and functional features that could be found admixed with malignant B cells within invaded lymph nodes and bone marrow. In agreement, numerous predictive biomarkers in follicular lymphoma reflect tumor niche composition and organization rather than genetic features of tumor cells. Moreover, genetic hits in follicular lymphoma are not only related to B cell-intrinsic effects but could support interactions with surrounding non-B cells. Conversely, DLBCL have been proposed as less dependent on lymph node architecture and the most popular prognostic classification of DLBCL tumors, that is GCB-DLBCL versus activated B-cell (ABC)-DLBCL, relies on tumor cell genetic characteristics reminiscent of their putative cell of origin and molecular transformation pathways. Importantly, both follicular lymphoma and DLBCL tumors are under a constant selective pressure from the immune system as revealed by the numerous genetic hits favoring immune escape.
Other reviews provide a description of follicular lymphoma/DLBCL genomic landscape and clonal architecture and detail the general concept of protumoral versus antitumoral microenvironment [4, 5] . This review will focus on the more recent concepts of tumor niche-derived cellular and noncellular supportive signals in B-cell lymphomas, how they are triggered, and their potential clinical impact on patient stratification and treatment.
IMMUNE ESCAPE MECHANISMS UNDER THE SPOTLIGHTS
In B-cell lymphomas, malignant cells are major histocompatibility complex (MHC) class II-expressing professional antigen-presenting cells and induction of antitumor innate, and adaptive immunity has been well documented. In agreement, follicular lymphoma has been one of the first tumor subtype in which tumor vaccines have been tested with a good biological response [6] and both tumor-associated macrophages (TAM) and natural killer (NK) cells largely contribute to the clinical efficacy of anti-CD20 antibodies. However, several immune escape mechanisms have been uncovered including reduction of tumor immunogenicity, inhibition of immune effectors, and infiltration by immunosuppressive cells (Fig. 1) .
First, tumor cells decrease their expression of MHC molecules to avoid recognition by CD8 and CD4 T cells. B2M genetic inactivation resulting in loss of MHC class I is more frequent in transformed follicular lymphoma and DLBCL, whereas lack of MHC class II expression is a common feature across lymphoma subtypes [7 && ,8,9] . Significantly, early loss-of-function mutations of CREB binding protein (CREBBP) found in about 60% of follicular lymphoma and 15% of DLBCL have been recently proposed as the major mechanism supporting the downregulation of MHC class II and the corresponding decreased T-cell activation and in situ infiltration [7 && ]. Mechanistically, CREBBP mutations disable H3K27 acetylation and favor BCL6-dependant transcriptional repression of genes regulating MHC class II expression and antigen presentation [10] .
The second driving mechanism of immune escape is the reduced antitumoral T/NK cell activity. Both follicular lymphoma-infiltrating and DLBCLinfiltrating cytotoxic T cells display an upregulation of coinhibitory receptors, an impaired lymphocyte function-associated antigen 1-dependent motility, and a decreased capacity to form functional immunological synapses with malignant cells [11] [12] [13] [14] [15] [16] [17] . Importantly, lymphocyte-activation gene 3, T-cell immunoglobulin and mucin-domain containing-3, and T-cell immunoglobulin and ITIM domain (TIGIT) have emerged recently as good markers of T-cell exhaustion in B-cell lymphomas, whereas programmed cell death 1 (PD-1) expression is not sufficient to distinguish exhausted from activated T cells, in particular in follicular lymphoma [18] . An important question remains the nature of the ligand-expressing cells. In fact, only 20-30% of DLBCL B cells, essentially some ABC-DLBCL and epstein barr virus pos DLBCL, and no follicular lymphoma B cell express programmed death-ligand 1 (PD-L1), whereas infiltrating PD-L1 pos myeloid cells could be detected in both DLBCL and follicular lymphoma [19] . The TIGIT ligands CD122 and CD155 were detected on follicular dendritic cells and endothelial cells inside follicular lymphoma follicles [13] . Of note, another important parameter to take into account when considering antitumor T-cell response is the impact of T-cell receptor (TCR) repertoire. Intratumoral TCR repertoire was reported to be abnormally narrow in DLBCL and this restriction of TCR diversity was associated with adverse outcome [20 & ]. Finally, NK cells could also be inhibited within lymphoma cell niches, either through expression of PD-1 or through interaction with lectin-like transcript 1, the ligand for the NK inhibitory receptor CD161 recently found to be strongly expressed by follicular lymphoma and GCB-DLBCL malignant B cells [21] . [22, 23] . Tfr have been previously identified within normal GC and interfere with T-cell help produced by follicular helper T cells (Tfh) thus negatively controlling the GC reaction [24] . In follicular lymphoma, Treg/Tfr are able to suppress not only CD4 pos T cells, including Tfh, but also follicular lymphoma B cells, suggesting that they could have indirect and direct antitumor activity [23] . Conversely, they could also inhibit cytotoxic T cells that are essentially found at the GC border in follicular lymphoma in agreement with a strongly suppressive microenvironment within invaded follicles [25, 26] . Such opposite functions could explain controversial results concerning the prognostic impact of FOXP3 pos Treg number and localization. This skewing of T-cell response toward regulatory phenotype is at least partly orchestrated by malignant follicular lymphoma B cells through the production of high amounts of the Treg recruiting chemokine CCL22, and the expression of CD70 and Inducible costimulator Ligand [23, 27, 28] . In addition to Treg, suppressive myeloid cells have emerged as important drivers of immune escape in B-cell lymphomas, as highlighted by the negative prognostic impact of a high number of circulating myeloid cells, including monocytes and neutrophils; a high number of CD68 pos or CD163 pos myeloid cells within lymphoma niches; a high level of markers related to myeloid suppressive functions, including soluble PD-L1, IL-10, and indoleamine-2,3 dioxygenase (IDO) [29] [30] [31] . Recently, specific attention has been paid to the role of MDSC in B-cell lymphomas. Two main cell subsets, monocytic (M)-MDSC and granulocytic (G)-MDSC, have been demonstrated to play potent immunosuppressive functions in cancers and inflammatory diseases. Both circulating M-MDSC and G-MDSC were found elevated in lymphoma patient peripheral blood and their abundance has been variably proposed as predictive of clinical outcome [32 & ,33] . The function of M-MDSC has been particularly well studied in DLBCL and was ascribed to their expression of S100A12, IL-10, and PD-L1, unlike to arginase 1 and IDO immunosuppressive enzymes [32 & ]. It has been demonstrated in murine models that MDSC could differentiate into TAM at the tumor site but the precise relationship between MDSC and TAM in human lymphomas remain unclear. Lymphoma-derived TAM have been shown to produce IDO and IL-4-induced gene 1 enzymes associated with tryptophan and phenylalanine catabolism, respectively [31, 34] . Finally, it is important to keep in mind that cancer-associated fibroblasts (CAF) could contribute to immune escape as recently highlighted in solid cancers [35] . Significantly, follicular lymphoma-infiltrating stromal cells overexpress Prostaglandin E2, a well known immunosuppressive factor [36] , and stromal cells were proposed to favor B-cell lymphoma growth in a murine model of lacrimal gland lymphoma through the recruitment of Treg and MDSC [37] .
KEY POINTS

B-CELL RECEPTOR AND MICROENVIRONMENT: A REVISITED PARADIGM
The central role of B-cell receptor (BCR) signaling in lymphomagenesis is now well documented. ABC-DLBCL tumors, the most aggressive forms of DLBCL, are addicted to nuclear factor-kappa B (NF-kB) activation and mutations in BCR components or downstream signaling effectors leading to a chronic active BCR signaling have been involved in this oncogenic NF-kB activity [38] . Significantly, chronic active BCR signaling retains the hallmarks of normal antigen-dependent signaling and a role for self-antigen recognition in the initiation and maintenance of BCR activation in ABC-DLBCL has been recently proposed [39] . In agreement, some of the recurrent genetic hits in ABC-DLBCL, such as the gain-offunction mutations in CD79A/B, cannot trigger BCR signaling de novo but amplify it. By contrast, GCB-DLBCL are dependent on activation of phosphoinositol 3 kinase/Akt by antigen-independent tonic BCR signaling, a process that could be favored by PTEN inactivation [40] . Of note, whereas GCB-DLBCL harbor an IgG BCR, ABC-DLBCL retain expression of an IgM BCR as a consequence of deletions in the Sm region of the productive IGH allele [41] . The unique cytoplasmic tails of IgM and IgG BCR produce qualitatively different signaling outputs in normal antigen-experienced B cells [42] . Moreover, switched memory B cells are prone to generate a large number of plasma cells, whereas IgM pos memory B cells reinitiate a GC reaction upon antigenic challenge [43, 44] . It would be important to understand whether differences between IgM versus IgG signaling contribute to differences between GCB-DLBCL and ABC-DLBCL pathogenesis. Significantly, a role for tumor microenvironment has recently emerged in the activation of BCR in follicular lymphoma patients. Specifically, although less than 25% of follicular lymphoma BCR, essentially of IgG isotype, are supposed to be selfreactive [45] , follicular lymphoma BCR is characterized by a selective pressure to retain an IgM BCR despite active class switch recombination process; the introduction of N-glycosylation sites within variable regions of immunoglobulin genes during somatic hypermutation in more than 80% of cases [46] . The maintenance of IgM BCR could contribute to the frozen GC phenotype of follicular lymphoma B cells that is established very early during lymphomagenesis process and is associated with a high risk of additional genetic events [47, 48] . Moreover, IgM follicular lymphoma BCR crosslinking triggers a stronger BCR activation than IgG follicular lymphoma BCR [49] . Importantly, follicular lymphoma-specific N-glycosylation sites are occupied by unusual glycans terminating at high mannose allowing an interaction with Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Nonintegrin (DC-SIGN) on the surface of follicular lymphoma TAM and a delayed but long-lasting BCR aggregation and activation in the absence of surface immunoglobulin endocytosis [49, 50] . Of note bacteria-derived lectins have also been shown to trigger follicular lymphoma BCR aggregation in vitro [51] . In this context, recurrent genetic alterations are thus associated with an increased capacity of tumor cells to interact with tumor microenvironment. Mutations in BCR/NF-kB signaling pathways have been recently described in about 30% of follicular lymphoma patients but their biological and clinical significance remain to be elucidated [52] .
TUMOR PERMISSIVE CELL MICROENVIRONMENT: A KEY ROLE FOR CANCER-ASSOCIATED FIBROBLASTS
Apart from BCR signaling, lymphoma microenvironment also delivers a combination of survival and growth signals that promote lymphoma development and drug resistance (Fig. 1) . It has long been assumed that tumor-supportive CD4 pos T cells are specifically amplified in follicular lymphoma, unlike DLBCL. Follicular lymphoma-infiltrating CD4 pos T cells display a CD10 pos Tfh phenotype, and overexpress CD40L and IL-4 involved in the direct stimulation of follicular lymphoma B-cell survival and stimulating TAM-B cell crosstalk [22, 53] . Indeed, Tfh-derived CD40L stimulates the capacity of normal and malignant B cells to respond to macrophage-derived IL-15 [54] , whereas IL-4 increases the expression of DC-SIGN on macrophages and membrane IgM on malignant B cells, thus favoring BCR/DC-SIGN interaction [49] . More recently, two other cell subsets, potentially involved in both follicular lymphoma and DLBCL, have been considered. The first one is tumor-associated neutrophils (TAN). Whereas TAM have been regularly presented as a major component of lymphoma cell niches, TAN have only been recently studied in these diseases. Significantly, DLBCL B cells produce IL-8 and recruit neutrophils able in turn to protect them from spontaneous and drug-induced apoptosis through expression of a proliferation-inducing ligand (APRIL) and CD11b [55, 56] . A high level of IL-8 could also be detected within follicular lymphoma cell niche even if neutrophils do not directly rescue primary follicular lymphoma B cells from apoptosis in vitro [57] . However, TAN could contribute to the activation of stromal cells, inducing their commitment into a follicular lymphoma-supportive phenotype.
In fact, tumor-promoting activities of CAF, including cancer cell proliferation and invasion, inflammation, and drug resistance, and their potential as attractive therapeutic targets have been recently described in solid cancer. Follicular lymphoma CAF have focused more attention than their DLBCL counterpart and have been described as lymphoid-like stromal cells exhibiting specific phenotypic and transcriptomic features (Fig. 2) . In particular, an upregulation of CXCL12 has been recently highlighted in lymph nodes and bone marrow follicular lymphoma-CAF contributing to B-cell homing and adhesion to protective cell niches [58 & ]. CAF directly support malignant follicular lymphoma and DLBCL B-cell growth in vitro through a panel of mechanisms only partially solved, including the production of hedgehog ligands and B-cell activating factor, and the upregulation of ABC multidrug resistance transporters and C-MYC/HDAC6 loop in tumor cells [59] . Recently, an elegant threedimensional organotypic culture model functionalized with variable integrin-specific ligands was used to support a role in B-cell lymphoma growth for CD106, the ligand of the a4b1 [very late antigen 4 (VLA-4)] integrin, that is CD106, a well known marker of mature lymphoid stromal cells, B-cell [60 && ]. In addition to this direct B-cell supportive function, follicular lymphoma-CAF were proposed as organizers of follicular lymphoma cell niche and their overexpression of CCL2 and IL-8 trigger the recruitment of monocytes and neutrophils [57, 61] . Significantly, follicular lymphoma-CAF could protect recruited neutrophils from apoptosis and convert recruited monocytes into proangiogenic and anti-inflammatory TAM-like cells. Similarly, follicular lymphoma-CAF were proposed to favor Tfh/Tfr polarization and survival ( [62] and unpublished data). New studies based on the analysis of ex-vivo sorted stromal cells will be useful to better understand B-NHL CAF heterogeneity and function.
TUMOR NICHE ARCHITECTURE: A ROLE FOR EXTRACELLULAR MATRIX AND EXTRACELLULAR VESICLES
In addition to adhesive and chemotactic factors expressed by stromal cells, little attention has been given to the acellular components of the reticular fiber networks that form the scaffold of normal and malignant secondary lymphoid organs. In addition to cell adhesion molecules, extracellular matrix (ECM)-derived integrin ligands, including a3b1 ligands, have been proposed to impact normal GC B-cell fate and survival [63] but their role in follicular lymphoma/DLBCL remains to be fully explored. A recent study has uncovered the importance of the matricellular protein secreted protein acidic and rich in cysteine (SPARC) in lymphoma niches. SPARC, a regulator of collagen deposition and organization, was found expressed not only in follicles but also in invaded bone marrow paratrabecular areas of follicular lymphoma and DLBCL and may thus represent a common regulatory element in both bone marrow and lymph nodes lymphoma Cancer-associated fibroblasts play a key role in tumor permissive microenvironment. Cancer-associated fibroblasts could directly favor malignant B-cell homing and survival through the production of chemokines, Hh ligands, BAFF, and adhesion molecules. In addition, they should be considered as organizers of lymphoma cell niche by triggering recruitment, and differentiation/polarization of follicular helper T cells, tumor-associated macrophages, and tumor-associated neutrophils, whereas they could contribute to the inhibition of immune effector cell activity. Conversely, malignant B cells themselves but also other components of the tumor niche contribute to the activation of cancer-associated fibroblasts. Importantly, besides stromal cells, acellular components, including extracellular matrix and extracellular vesicles, participate to the construction and architecture of lymphoma cell niche. BAFF, B-cell activating factor.
niches [64] . Sparc deletion in mice is associated with defective collagen assembly and a loss of neutrophil inhibitory signal, promoting aberrant crosstalk between neutrophil extracellular traps and B cells and favoring transition from autoimmunity to lymphoma [65 & ]. Overexpression of SPARC was associated with a good prognosis in DLBCL [66] , whereas an altered pattern of SPARC expression was found in early follicular lymphoma patients [65 & ]. Considering ECM remodeling components, it has been recently demonstrated that heparanase, the predominant endoglycosidase able to cleave heparan sulfate side chains of proteoglycans, is strongly expressed in about 50% of follicular lymphomas and DLBCL [67] . Heparanase triggers ECM disassembly and increases bioavailability of growth factors bound to heparan sulfates. Significantly, heparanase-neutralizing antibodies inhibit B-cell lymphoma growth and metastasis in mouse xenograft models without direct cytotoxic activity. Finally, ECM organization and mechanical forces also regulate three-dimensional tumor architecture and impact tumor evolution. Mechanotransduction may originate from two mechanisms inside tumors: external mechanical forces (i.e., compressive stress) and/or internal mechanical forces (i.e., cell-generated contractility). Whereas recent studies based on multicellular aggregates of lymphoma B cells have proposed to evaluate some of these parameters [68] , they did not include stromal cells and compressive forces thus limiting their potential impact. Significantly, normal lymph node expansion and contraction specifically rely on the podoplanin-dependent contractile activity of lymphoid stromal cells [69] and podoplanin is downregulated in follicular lymphoma lymph nodes [58 & ], in association with a reduced tissue stiffness and expansion of malignant B cells in enlarged lymph nodes. Finally, it is important to keep in mind that ECM density and orientation also impact T-cell recruitment within tumor, as initially highlighted in lung cancer [70] , a process that could both affect protumoral and antitumoral T cells in B-cell lymphomas.
Extracellular vesicles, including microvesicles and exosomes, represent a new component of Bcell/niche crosstalk. Released by tumor cells, they could encapsulate different cellular components, including proteins, DNA, or noncoding RNA, and alter the phenotype and functional properties of distant cells. Even if they have been less studied than extracellular vesicles from solid tumors, recent interesting studies proposed that extracellular vesicles produced by malignant B cells could exert different roles including the induction of CAF differentiation, as proposed in chronic lymphocytic leukemia [71] ; the protection of tumor B cells from rituximab through the trapping of anti-CD20 antibody [72] ; the transfer of the constitutively active membrane-associated protein MyD88 L265P leading to the propagation of proinflammatory stimuli in recipient surrounding cells [73] . Additional evaluation of the composition and specific roles of lymphoma B cell-derived extracellular vesicles as well as the function of extracellular vesicles produced by lymphoma microenvironment will be an important research path in the coming future.
GENETIC ALTERATIONS AND MICROENVIRONMENT: THE MISSING LINK
Some of the recurrent genetic alterations in follicular lymphoma modulate the crosstalk between malignant B cells and their supportive niche, as described above for CREBBP mutations related to the loss of MHC class II-dependent recognition by antitumoral CD4
pos T cells and for the N-glycosylation of variable immunoglobulin genes leading to a BCR/DC-SIGN interaction bridging B cells and TAM [7 && ,49] (Fig. 3) . Significantly, some somatic mutations could also functionally impact follicular lymphoma microenvironment and are thus related to the mechanisms of tumor niche re-education by tumor cells. In particular, loss-of-function alterations of herpesvirus entry mediator (HVEM)/ TNFRSF14 found in 50% of follicular lymphoma patients alleviate the inhibitory signal provided by HVEM interaction with its receptor B-and T-lymphocyte attenuator (BTLA). Disruption of HVEM/ BTLA interaction has been shown to trigger, in vavP-BCL2 follicular lymphoma mouse models and in follicular lymphoma patients, both B-cell autonomous activation by favoring BCR signaling but also B-cell extrinsic activation of lymphoma microenvironment [74 && ]. In particular, HVEM inactivation triggers an amplification of BTLA hi Tfh producing high amount of IL-4, TNF-a, and lymphotoxin a1b2. Significantly, TNF-a and lymphotoxin a1b2 are the two nonredundant factors involved in lymphoid stroma differentiation and maintenance, whereas IL-4 has been shown to induce CXCL12 upregulation in lymphoid stromal cells [58 & ]. In agreement, follicular lymphoma-CAF are activated, display a lymphoid phenotype, and overexpress CXCL12. Such cell network is also reinforces by a direct impact of B cells on stromal cells. In fact, whereas follicular lymphoma B cells could not induce CXCL12 in stromal cells, in agreement with their lack of IL-4 expression, they could contribute to their differentiation into lymphoid stromal cells producing CCL2 and IL-8, in a TNF-dependent manner [57, 61] . Significantly, TNF production is also increased in B cells from HVEM-deficient mice.
Hence, HVEM alterations contribute to the organization of a functional 'ménage-à-trois' including malignant B cells, stromal cells, and Tfh. The detailed study of tumor microenvironment composition and organization in the newly developed follicular lymphoma/DLBCL mouse models mimicking recurrent oncogenetic hits will be highly useful to better understand the coevolution of lymphoma cells and their permissive niche.
POTENTIAL CLINICAL IMPACT OF TUMOR/ MICROENVIRONMENT CROSSTALK
The identification of protumoral and antitumoral signals delivered by the microenvironment and the understanding of how this microenvironment progressively coevolved with tumor cells in a highly dynamic crosstalk have paved the way for the design of new therapeutic strategies. At least three main approaches with complementary impacts could be considered. The first one aims at stimulating immune effector cells. In addition to pleiotropic immunomodulators, including lenalidomide, immune checkpoint inhibitors, in particular anti-PD-1/anti-PD-L1 antibodies, are under intensive evaluation in GC-derived B-cell lymphomas. Significantly, follicular lymphomas have been recently segregated into 'inflamed' versus 'uninflamed' subgroups based on mutational load and T effector gene signature, with an improved survival in the inflamed subset [75] . To what extend the identification of immunologically distinct lymphoma entities will be relevant for patient stratification in immunotherapy clinical trials deserves further investigation. More recently, new strategies emerge with the aim to stimulate TAM and/or TAN antitumor innate immune activity. As an example, monospecific or bispecific antibodies targeting SIRP-a and disrupting its binding to the 'don't eat me' receptor CD47 expressed on lymphoma B cells are promising candidates to increase antibody-dependent cell phagocytosis ( [76] and unpublished data). The second strategy would be to target B-cell adhesion and/or retention within tumor niches and both the natalizumab anti-VLA-4 antibody and the disruption of the CXCL12/CXCR4 axis have shown synergistic effects with anti-CD20 antibodies [77, 78] . Significantly, the main BCR inhibitors do not only target BCR signaling but also modulate Tcell response and impair chemokine networks thus reducing B-cell retention in protective stromal microenvironment [79] . Finally, the specific targeting of microenvironment cell components, based on the better understanding of their heterogeneity and plasticity, is still in its infancy but has recently became a reality. In fact, Anti-TGFb1 antibodies were proposed to reprogram CAF and increase Tcell infiltration within the tumor bed of urothelial tumors, thus synergizing with anti-PD-L1 antibodies [80] . In another study, chimeric-antigen-receptor-T (CAR-T) cells cotargeting tumor cells and immunosuppressive/tumor-supportive TAM, both expressing CD123 in Hodgkin's lymphomas, have paved the way for considering the use of targeted therapies redirected toward tumor microenvironment [81] .
DC-SIGN
CONCLUSION
The development of high-throughput quantitative strategies, including multicolor flow cytometry, mass cytometry, functional assays on sorted cell subsets, single-cell quantitative-PCR/RNAseq strategies, or TCR sequencing, has provided new insights on the number, phenotype, and function of the main components of B-cell lymphoma microenvironment. However, new strategies are needed to elucidate the network of cell interactions that regulate in situ the organization of lymphoma cell niches, to decipher the spatial and kinetic heterogeneity of tumor microenvironment, and to integrate it with corresponding tumor cell heterogeneity. In addition, the set up of relevant testing models, including lymphoma mouse models and threedimensional organoids mixing various cell subsets, ECM components, and mechanical constraints, is now mandatory to design adequate tailored efficient therapeutic strategies in B-NHL.
